Search for authorsSearch for similar articles
4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Informal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregivers’ Lives

      research-article
      1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 16 , 17 , 18 , 19 , 1 , 1 , 1 , 18 , 19 , 20 , 21 , 21 , 22 , 23 , 24 , 5 , 2 , 2 , 1 , 1 , *
      ,
      Brain Sciences
      MDPI
      amyotrophic lateral sclerosis (ALS), informal caregiving, caregiver burden, functional status, decreasing autonomy, depression, anxiety, health-related quality of life, socioeconomic status, psychological support

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes progressive autonomy loss and need for care. This does not only affect patients themselves, but also the patients’ informal caregivers (CGs) in their health, personal and professional lives. The big efforts of this multi-center study were not only to evaluate the caregivers’ burden and to identify its predictors, but it also should provide a specific understanding of the needs of ALS patients’ CGs and fill the gap of knowledge on their personal and work lives. Using standardized questionnaires, primary data from patients and their main informal CGs ( n = 249) were collected. Patients’ functional status and disease severity were evaluated using the Barthel Index, the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) and the King’s Stages for ALS. The caregivers’ burden was recorded by the Zarit Burden Interview (ZBI). Comorbid anxiety and depression of caregivers were assessed by the Hospital Anxiety and Depression Scale. Additionally, the EuroQol Five Dimension Five Level Scale evaluated their health-related quality of life. The caregivers’ burden was high (mean ZBI = 26/88, 0 = no burden, ≥24 = highly burdened) and correlated with patients’ functional status (r p = −0.555, p < 0.001, n = 242). It was influenced by the CGs’ own mental health issues due to caregiving (+11.36, 95% CI [6.84; 15.87], p < 0.001), patients’ wheelchair dependency (+9.30, 95% CI [5.94; 12.66], p < 0.001) and was interrelated with the CGs’ depression (r p = 0.627, p < 0.001, n = 234), anxiety (r p = 0.550, p < 0.001, n = 234), and poorer physical condition (r p = −0.362, p < 0.001, n = 237). Moreover, female CGs showed symptoms of anxiety more often, which also correlated with the patients’ impairment in daily routine (r s = −0.280, p < 0.001, n = 169). As increasing disease severity, along with decreasing autonomy, was the main predictor of caregiver burden and showed to create relevant (negative) implications on CGs’ lives, patient care and supportive therapies should address this issue. Moreover, in order to preserve the mental and physical health of the CGs, new concepts of care have to focus on both, on not only patients but also their CGs and gender-associated specific issues. As caregiving in ALS also significantly influences the socioeconomic status by restrictions in CGs’ work lives and income, and the main reported needs being lack of psychological support and a high bureaucracy, the situation of CGs needs more attention. Apart from their own multi-disciplinary medical and psychological care, more support in care and patient management issues is required.

          Related collections

          Most cited references91

          • Record: found
          • Abstract: not found
          • Article: not found

          The Hospital Anxiety and Depression Scale

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)

            Purpose This article introduces the new 5-level EQ-5D (EQ-5D-5L) health status measure. Methods EQ-5D currently measures health using three levels of severity in five dimensions. A EuroQol Group task force was established to find ways of improving the instrument’s sensitivity and reducing ceiling effects by increasing the number of severity levels. The study was performed in the United Kingdom and Spain. Severity labels for 5 levels in each dimension were identified using response scaling. Focus groups were used to investigate the face and content validity of the new versions, including hypothetical health states generated from those versions. Results Selecting labels at approximately the 25th, 50th, and 75th centiles produced two alternative 5-level versions. Focus group work showed a slight preference for the wording ‘slight-moderate-severe’ problems, with anchors of ‘no problems’ and ‘unable to do’ in the EQ-5D functional dimensions. Similar wording was used in the Pain/Discomfort and Anxiety/Depression dimensions. Hypothetical health states were well understood though participants stressed the need for the internal coherence of health states. Conclusions A 5-level version of the EQ-5D has been developed by the EuroQol Group. Further testing is required to determine whether the new version improves sensitivity and reduces ceiling effects.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.

              A five-level version of the EuroQol five-dimensional (EQ-5D) descriptive system (EQ-5D-5L) has been developed, but value sets based on preferences directly elicited from representative general population samples are not yet available. The objective of this study was to develop values sets for the EQ-5D-5L by means of a mapping ("crosswalk") approach to the currently available three-level version of the EQ-5D (EQ-5D-3L) values sets. The EQ-5D-3L and EQ-5D-5L descriptive systems were coadministered to respondents with conditions of varying severity to ensure a broad range of levels of health across EQ-5D questionnaire dimensions. We explored four models to generate value sets for the EQ-5D-5L: linear regression, nonparametric statistics, ordered logistic regression, and item-response theory. Criteria for the preferred model included theoretical background, statistical fit, predictive power, and parsimony. A total of 3691 respondents were included. All models had similar fit statistics. Predictive power was slightly better for the nonparametric and ordered logistic regression models. In considering all criteria, the nonparametric model was selected as most suitable for generating values for the EQ-5D-5L. The nonparametric model was preferred for its simplicity while performing similarly to the other models. Being independent of the value set that is used, it can be applied to transform any EQ-5D-3L value set into EQ-5D-5L index values. Strengths of this approach include compatibility with three-level value sets. A limitation of any crosswalk is that the range of index values is restricted to the range of the EQ-5D-3L value sets. Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Role: Academic Editor
                Journal
                Brain Sci
                Brain Sci
                brainsci
                Brain Sciences
                MDPI
                2076-3425
                04 June 2021
                June 2021
                : 11
                : 6
                : 748
                Affiliations
                [1 ]Department of Neurology, Hannover Medical School, 30625 Hannover, Germany; Schischlevskij.Pavel@ 123456mh-hannover.de (P.S.); Mueschen.Lars@ 123456mh-hannover.de (L.H.M.); dr.almaosmanovic@ 123456gmail.com (A.O.); Binz.Camilla@ 123456mh-hannover.de (C.B.); Petri.Susanne@ 123456mh-hannover.de (S.P.)
                [2 ]Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany; isabell.cordts@ 123456tum.de (I.C.); marcus.deschauer@ 123456mri.tum.de (M.D.); paul.lingor@ 123456tum.de (P.L.)
                [3 ]Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany; Rene.Guenther@ 123456uniklinikum-dresden.de
                [4 ]German Center for Neurodegenerative Diseases (DZNE), 01307 Dresden, Germany
                [5 ]Department of Neurology, University Medicine Essen, 45147 Essen, Germany; benjamin.stolte@ 123456uk-essen.de (B.S.); tim.hagenacker@ 123456uk-essen.de (T.H.)
                [6 ]Department of Neurology, University of Würzburg, 97080 Würzburg, Germany; Zeller_D@ 123456ukw.de
                [7 ]Hoher Meißner Clinic, Neurology, 37242 Bad Sooden-Allendorf, Germany; Schroeter@ 123456reha-klinik.de
                [8 ]Department of Neurology, Ruhr-University Bochum, BG-Kliniken Bergmannsheil, 44789 Bochum, Germany; ute.weyen@ 123456bergmannsheil.de
                [9 ]Department of Molecular Neurology, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany; Martin.Regensburger@ 123456uk-erlangen.de
                [10 ]Department of Neurology, Diakonissen Hospital Mannheim, 68163 Mannheim, Germany; j.wolf@ 123456diako-mannheim.de
                [11 ]Department of Neurology, Martin-Luther University Halle/Saale, 06120 Halle, Germany; Ilka.Schneider@ 123456sanktgeorg.de
                [12 ]Department of Neurology, Klinikum Sankt Georg, 04129 Leipzig, Germany
                [13 ]Translational Neurodegeneration Section “Albrecht-Kossel”, Department of Neurology, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany; Andreas.Hermann@ 123456med.uni-rostock.de
                [14 ]German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, 18147 Rostock, Germany
                [15 ]Department of Neurology, University Hospital Leipzig, 04103 Leipzig, Germany; Moritz.Metelmann@ 123456medizin.uni-leipzig.de
                [16 ]Department of Neurology, University of Regensburg, 93053 Regensburg, Germany; zacharias.kohl@ 123456klinik.uni-regensburg.de (Z.K.); Ralf.Linker@ 123456klinik.uni-regensburg.de (R.A.L.)
                [17 ]Department of Neurology, University Medicine Göttingen, 37075 Göttingen, Germany; jkoch@ 123456med.uni-goettingen.de
                [18 ]Department of Neurology, Friedrich-Baur Institute, University Hospital, Ludwig Maximilian University of Munich, 80336 Munich, Germany; Claudia.Stendel@ 123456med.uni-muenchen.de (C.S.); Thomas.Klopstock@ 123456med.uni-muenchen.de (T.K.)
                [19 ]German Center for Neurodegenerative Diseases (DZNE), 80336 Munich, Germany
                [20 ]Munich Cluster for Systems Neurology (SyNergy), 80336 Munich, Germany
                [21 ]Department of Neurology, University of Ulm, 89081 Ulm, Germany; johannes.dorst@ 123456rku.de (J.D.); albert.ludolph@ 123456rku.de (A.C.L.)
                [22 ]German Center for Neurodegenerative Diseases (DZNE), 89081 Ulm, Germany
                [23 ]Department of Neurology, Institute of Translational Neurology, University Hospital Münster, 48149 Münster, Germany; Matthias.Boentert@ 123456ukmuenster.de
                [24 ]Department of Medicine, UKM Marienhospital, 48565 Steinfurt, Germany
                Author notes
                Author information
                https://orcid.org/0000-0002-2774-067X
                https://orcid.org/0000-0002-2172-7386
                https://orcid.org/0000-0002-7364-7791
                https://orcid.org/0000-0002-4147-8866
                https://orcid.org/0000-0002-6012-8423
                https://orcid.org/0000-0001-6133-1397
                https://orcid.org/0000-0002-3631-3450
                https://orcid.org/0000-0001-9362-7096
                https://orcid.org/0000-0001-5621-4487
                Article
                brainsci-11-00748
                10.3390/brainsci11060748
                8228206
                34200087
                8e9b5782-99b3-487a-b47b-9f03d80ccff2
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 06 April 2021
                : 31 May 2021
                Categories
                Article

                amyotrophic lateral sclerosis (als),informal caregiving,caregiver burden,functional status,decreasing autonomy,depression,anxiety,health-related quality of life,socioeconomic status,psychological support

                Comments

                Comment on this article